SOX10 and neoplasm: Using Vemurafenib to treat advanced melanoma with an observed BRAFV600E mutation, cells acquiring a somatic SOX10 mutation that hinders proper gene product formation allow the tumor to grow unchallenged by therapeutic treatments that would otherwise be effective [42,44].